Law360, New York (October 06, 2009) -- Genzyme Corp. has accused Endo Pharmaceuticals Inc. of infringing a patent for Renagel by seeking regulatory permission to sell a generic version of the kidney disease treatment in the U.S. before the patent expires.
The complaint — filed Thursday in the U.S. District Court for the District of Maryland — cites an Aug. 18 letter the generics maker sent Genzyme informing the company that...
